Shots:

• The sNDA is based on the P-III (JUPITER-02) study to evaluate toripalimab + CT in patients with locally recurrent or metastatic NPC. The study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center
• The results showed that patients with toripalimab had better PFS, high ORR & longer DoR along with survival benefits regardless of PD-L1 expression status with a manageable safety profile. The results were presented at ASCO 2021
• Toripalimab is the 4th approved indication in China while Coherus gets the rights to develop & commercialize toripalimab in the US & Canada in 2021. The companies plan to file an additional BLA of toripalimab with the US FDA for multiple cancer types

Ref: Globe Newswire | Image: Junshi